Vitiligo: Research & Clinical Takeaways

A cross-sectional study assessed how accurately ICD-10 codes identify patients with vitiligo.

For patients with vitiligo, combining cyclosporine with narrowband UV‑B may be oncologically safe according to this nationwide cohort.

In routine practice, oral JAK inhibitors produced meaningful repigmentation for many patients with vitiligo; extending treatment beyond 6 months was...

A cohort study examined the association between pediatric vitiligo and auditory and ocular manifestations.

EPS significantly slowed depigmentation versus untreated mice. Treated mice had fewer cutaneous CD8+ T cells, more regulatory T cells, more splenic...

COVID‑19 was associated with higher rates of chronic urticaria, vitiligo, alopecia areata, and herpes zoster versus matched controls after...

Monitor for autoimmune and autoinflammatory connective tissue disorders after COVID-19, with extra vigilance after severe infection, during...

Do not rely solely on physician-rated severity or visibility to gauge impact. Routinely identify stigmatization and bullying and track change with...

For dermatology patients, short-term systemic JAK/TYK2 inhibitor use did not increase MACE or VTE versus placebo over a median 16 weeks. This...

After transplant—especially HSCT and when GVHD is present—plan regular skin checks and coordinate dermatology follow-up for early detection of...

In dermatology RCTs, JAK inhibitors did not increase short-term risk of MACE, death, or VTE vs controls. Use routine cardiovascular/VTE risk...

Vitiligo was associated with lower all-cause and multiple cause-specific mortality compared with matched controls in this large Korean cohort. This...